Effect of Permixon on human prostate cell growth: Lack of apoptotic action

Prostate

Volumn 61, Issue 1, 2004, Pages 73-80

  Hill, Brian ^a   Kyprianou, Natasha ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

5 reductase; Apoptosis; Cell proliferation; Permixon; Prostate cancer

Indexed keywords

CASPASE 3; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; SABAL; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; PLANT EXTRACTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SERENOA; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 4143150711     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20088     Document Type: Article

References (31)

1. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-273.
2. Kyprianou N, Isaacs JT. Programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122:552-562.
3. Kyprianou N, Tu H, Jacobs SC. Apoptotic vs. proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-672.
4. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis: A growth regulator and a therapeutic target. Cell Tissue Res 2000;301:152-162.
5. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461-475.
6. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α reductase suppresses prostatic dihydrotestosterone in men wih benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
7. McConnell JD, Btuskewitz R, Walsh PC, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. For the finasteride long-term efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 1998;338:557-563.
8. Riittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence of atrophy and apoptosis in the prostate of men given finasteride. J Clin Endocrinol Metab 1996;81:814-819.
9. Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001;46: 45-51.
10. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: An update. Urology 1999;53:671-674.
11. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000;163:1408-1414.
12. Marks LS, Tyler VE. Saw plametto extract: Newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology 1999;53:457-461.
13. Ravenna L, Di Silverio F, Russo M, Sarvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E. Effects of the lipodosterolic extract of Serenoa repens on human prostatic cell lines. Prostate 1996;29:219-230.
14. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37: 77-83.
15. Carraro J-C, Raynaud J-P, Koch G, Chisholm GD, Di Silverio F, Teillac P, Calais Da Silva F, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate 1996;29:231-240.
16. Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Di Silverio F. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide. J Androl 1997;18:488-494.
17. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar) a 5α-reductase inhibitor, and various commercial plant extracts in vitro and in in vivo and in vitro 5α-reductase inhibition. Prostate 1993;22:43-51.
18. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Ventri RW, Santos PBC, Stonebrook KA, de Kernion JB. Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451-1456.
19. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): A 5α-reductase type I and II inhibitor-new evidence on in a coculture model of BPH. Prostate 1999;40: 232-241.
20. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K. Myristotelic, a cytotoxic component of the extract from Serena repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47:59-65.
21. Vacherot F, Azzouz M, Gil-Diex-de-Medina S, Colombel M, De La Taille A, Belda M-A L, Abbou C, Raynaud J-P, Chopin DK. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSERSr, Permixon) in benign prostatic hyperplasia. Prostate 2000;45:259-266.
22. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-338.
23. Paubert-Baquet M, Couse H, Raynaud JP, Mencia-Huerta JM, Banquet P. Effect of lipidosterolic extract of Serenoa repens (permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33:340-347.
24. Guo Y, Kyprianou N. Restoration of TGF-β signaling pathway suppresses tumorigenicity of human prostate cancer cells via induction of caspase-1 mediated apoptosis. Cancer Res 1999;59: 1366-1371.
25. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-β induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 2001;142:2419-2426.
26. Benning CM, Kyprianou N. Quinazoline-derived adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor-independent mechanism. Cancer Res 2002;62: 597-602.
27. Wolf BB, Green DR Suicidal tendencies: Apoptotic cell death by caspase family of proteinases. J Biol Chem 1999;274:11549-11556.
28. Bayne CW, Ross M, Donelly F, Habib FK. The selectivity and specificity of the actions of the lipdo-sterolic extract of Serona repens (Permixon) for the prostate. J Urol 2000;164: 876-881.
29. Veltri RW, Marks LS, Miller MC, Bales WD, Fan J, Macairan ML, Epstein JI, Partin AW. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: Evidence for a possible molecular mechanism. Urology 2002; 60:617-622.
30. Briley M, Carilla E, Fauran F. Permixon, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in the rat prostate. Br J Pharmacol 1983;79: 327-336.
31. Savory JGA, May D, Reich T, La Casse EC, Lakins J, Tenniswood M, Raymond Y, Hache RJG, Sikorska M, Lefebvre YA. 5 reductase type I is localized to the outer nuclear membrane. Mol Cell Endocrinol 1995;110:137-147.